Key facts
- This page summarizes Dhavalkumar Dhirajlal Patel's Form 3 filing for Sana Biotechnology, Inc. (SANA).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2026, 16:15.
Dhavalkumar Dhirajlal Patel - 24 Mar 2026 Form 3 Insider Report for Sana Biotechnology, Inc. (SANA)
- Reporting relationship
- EVP, Chief Scientific Officer
- Issuer ticker
- SANA
- Reported as of
- 24 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dhavalkumar Dhirajlal Patel filed Form 3 for Sana Biotechnology, Inc. (SANA) on 27 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002115339
Primary reporting owner
PATEL DHAVALKUMAR DHIRAJLAL
- Relationship
- EVP, Chief Scientific Officer
- Address
- C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE
- Signature
- /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel
- Signature date
- 27 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SANA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 99,510
- Date
- 24 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SANA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 515,000
- Exercise price
- $5.84
- Footnotes
- F1
SANA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 375,000
- Exercise price
- $2.55
- Footnotes
- F2
SANA
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 506,250
- Exercise price
- $3.41
- Footnotes
- F3
SANA
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 375,000
- Exercise price
- Footnotes
- F4, F5
SANA
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 62,500
- Exercise price
- Footnotes
- F4, F6
SANA
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 112,500
- Exercise price
- Footnotes
- F4, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The option vested as to 25% of the shares underlying the option on August 26, 2025 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. ("Sana") as an employee, consultant, director or officer of Sana through each such date.
Footnote F2
The option vested as to 25% of the shares underlying the option on March 6, 2026 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Footnote F3
The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
Footnote F5
The award vested as to 25% of the restricted stock units on August 26, 2025 and the remaining restricted stock units will vest in three equal installments on each of August 26, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Footnote F6
The award vested as to 25% of the restricted stock units on March 6, 2026 and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Footnote F7
The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.